Simple Plex™ Assays used to measure Human Thymus and Activation-Regulated Chemokine in Hodgkin Lymphoma patients
Wednesday, January 31, 2018 - 06:59
By Erin Christey, Simple Plex Product Manager
Optimizing therapies for patients with Hodgkin lymphoma relies upon the identification of prognostic factors that will predict outcomes and guide treatment approaches. A cross-departmental group at the Memorial Sloan Kettering Cancer Center recently published their findings on how baseline metabolic tumor volume is a predictive factor for patients with relapsed/refractory Hodgkin lymphoma.
Following standards set by the Clinical Laboratory Improvement Amendments (CLIA), they measured pre- and post-therapy levels of TARC (cysteine-cysteine thymus and activation related chemokine) with the Ella automated immunoassay platform and Simple Plex™ TARC assay. The precise and reliable method of measuring this chemokine at both low and elevated levels enabled the research group’s decision to expand its evaluation to a second cohort in the study.
Learn more about Simple Plex